Supplementary Information

Prevention of Acute Kidney Injury by Low Intensity Pulsed Ultrasound via

anti-inflammation and anti-apoptosis

Chih-Kang Chiang,^{1,2,†} Jui-Zhi Loh,^{1,†} Ting-Hua Yang,^{3,†} Kuo-Tong Huang,⁴ Cheng-Tien Wu,^{5,6} Siao-Syun Guan,⁷ Shing-Hwa Liu,^{1,8,9,*} Kuan-Yu Hung^{4,*}

Supplementary Figure 1.

Effects of LIPUS on hypoxia/reoxygenation (H/R)-induced cell viability inhibition in renal tubule NRK52E cells. Cells were treated with H/R (6 h/24 h) with or without LIPUS treatment. LIPUS (100 mW/cm²) was performed to the cell culture for a period of 15 min before the beginning of the experiment (H/R). The cell viability was determined by MTT assay. Data are presented as means \pm SEM (n = 7). **p* < 0.05 versus control. #*p* < 0.05 versus H/R alone.



Supplementary Figure 2.

Effects of LIPUS on the renal injury in an acute kidney injury (AKI) mouse model of unilateral ischemia/reperfusion injury (IRI) with contralateral nephrectomy. Animals were euthanized 48 hours after IRI or sham surgery with or without LIPUS treatment. The LIPUS treatment (100 mW/cm² intensity) was performed before IRI procedure and after IRI until the day of euthanization. (A) The serum blood urea nitrogen (BUN, a) and creatinine (b) levels were shown. (B) Renal tissues were stained with Periodic Acid-Schiff (PAS) and pathological changes were observed under light microscope. Histological score was also recorded. Data are presented as mean±SEM (n=4). **p* < 0.05 versus sham; # *p* < 0.05 versus IRI alone. Scale bar: 50 µm.



Supplementary Figure 3.

LIPUS by itself did not affect the renal function and morphology in sham control mice. The normal control mice with or without LIPUS treatment were euthanized 7 days after sham surgery. The LIPUS treatment (30 and 100 mW/cm² intensity) was performed before sham surgery and after sham surgery until the day of euthanization. (A) The serum blood urea nitrogen (BUN, a) and creatinine (b) levels were shown. (B) Renal tissues were stained with Periodic Acid-Schiff (PAS) and pathological changes were observed under light

microscope. Histological score was also recorded. Data are presented as mean \pm SEM (n=4). Scale bar: 100 μ m.



Supplementary Figure 4.

Schematic representation of induction of unilateral IRI mice with contralateral nephrectomy in the presence or absence of LIPUS treatment.



Supplementary Figure 5. Western blot raw data

(1). Cell model: C: control, H: H2O2 or hypoxia/reoxygenation (H/R), L: LIPUS

(2). AKI (IRI, 48 h) mouse model: S: sham, IRI: IRI alone, L: IRI+LIPUS

(1). Cell model

1. Figure 1B

Treatment: H2O2 for 24 h (Control, H2O2, H2O2+LIPUS, LIPUS); LIPUS 100 mW/cm² Tissue: NRK52E cells Protein: iNOS (130 kDa)



2. Figure 1B

Treatment: H2O2 for 24 h (Control, H2O2, H2O2+LIPUS, LIPUS); LIPUS 100 mW/cm² Tissue: NRK52E cells Protein: Cox-2 (72 kDa)



shown in Fig. 1B

3. Figure 1B

Treatment: H2O2 for 24 h (Control, H2O2, H2O2+LIPUS, LIPUS); LIPUS 100 mW/cm² Tissue: NRK52E cells Protein: p-p65 (65 kDa)



shown in Fig. 1B

4. Figure 1B

Treatment: H2O2 for 24 h (Control, H2O2, H2O2+LIPUS, LIPUS); LIPUS 100 mW/cm² Tissue: NRK52E cells Protein: p65 (65 kDa)



shown in Fig. 1B

5. Figure 1B

Treatment: H2O2 for 24 h (Control, H2O2, H2O2+LIPUS, LIPUS); LIPUS 100 mW/cm² Tissue: NRK52E cells Protein: β -actin (43 kDa)



6. Figure 2A

```
Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 30 mW/cm<sup>2</sup>
Tissue: NRK52E cells
Protein: Bax (20 kDa)
```



7. Figure 2A

Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 30 mW/cm² Tissue: NRK52E cells Protein: Bcl-2 (26 kDa)



8. Figure 2A

```
Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 30 mW/cm<sup>2</sup>
Tissue: NRK52E cells
Protein: CHOP (27 kDa)
```



9. Figure 2A

```
Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 30 mW/cm<sup>2</sup>
Tissue: NRK52E cells
Protein: cleaved caspase-3 (17 kDa)
```



10. Figure 2A

```
Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 30 mW/cm<sup>2</sup>
Tissue: NRK52E cells
Protein: COX-2 (72 kDa)
```



11. Figure 2A

Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 100 mW/cm² Tissue: NRK52E cells Protein: β-actin (43 kDa)



12. Figure 2B

Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 100 mW/cm² Tissue: NRK52E cells Protein: Bax (20 kDa)



13. Figure 2B

Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 100 mW/cm² Tissue: NRK52E cells Protein: Bcl-2 (26 kDa)



14. Figure 2B

Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 100 mW/cm² Tissue: NRK52E cells Protein: CHOP (27 kDa)



15. Figure 2B

```
Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 100 mW/cm<sup>2</sup>
Tissue: NRK52E cells
Protein: cleaved caspase-3 (17 kDa)
```



16. Figure 2B

Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 100 mW/cm² Tissue: NRK52E cells Protein: COX-2 (72 kDa)



17. Figure 2B

Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 100 mW/cm² Tissue: NRK52E cells Protein: β -actin (43 kDa)



18. Figure 3

Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 100 mW/cm² Tissue: NRK52E cells Protein: SOD1 (18 kDa)



19. Figure 3

Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 100 mW/cm² Tissue: NRK52E cells Protein: catalase (60 kDa)



20. Figure 3

Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 100 mW/cm² Tissue: NRK52E cells Protein: α -Klotho (116 kDa)



21. Figure 3



Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 100 mW/cm² Tissue: NRK52E cells Protein: Sirt1 (120 kDa)

22. Figure 3

Treatment: H/R (6h/24h) [Control, H/R (H), H/R+LIPUS, LIPUS]; LIPUS 100 mW/cm² Tissue: NRK52E cells Protein: β -actin (43 kDa)



(2). AKI (IRI 48 h) mouse model

1. Figure 5

Treatment: AKI-48h (sham, IRI, IRI+LIPUS) Tissue: Kidney Protein: GRP78 (78 kDa)



2. Figure 5

Treatment: AKI-48h (sham, IRI, IRI+LIPUS) Tissue: Kidney Protein: CHOP (27 kDa)



3. Figure 5

Treatment: AKI-48h (sham, IRI, IRI+LIPUS) Tissue: Kidney Protein: Bcl-2 (26 kDa)



4. Figure 5

Treatment: AKI-48h (sham, IRI, IRI+LIPUS) Tissue: Kidney Protein: Bax (20 kDa)



5. Figure 5

Treatment: AKI-48h (sham.IRI.IRI+LIPUS) Tissue: Kidney Protein: Cleaved Caspase-3 (17, 19 kDa)



shown in Fig. 5

6. Figure 5



Treatment: AKI-48h (sham.IRI.IRI+LIPUS)



7. Figure 6A

Treatment: AKI-48h (sham, IRI, IRI+LIPUS) Tissue: Kidney Protein: SOD1 (18 kDa)



8. Figure 6A



9. Figures 5 and 6A

Treatment: AKI-48h (sham, IRI, IRI+LIPUS) Tissue: Kidney Protein: β-actin (43 kDa)



10. Figure 8A-a

Treatment: AKI-48h (sham, IRI, IRI+LIPUS) Tissue: Kidney Protein: Ly6g (21-25 kDa)



11. Figure 8A-a

Treatment: AKI-48h (sham, IRI, IRI+LIPUS) Tissue: Kidney Protein: CD68 (polyclonal antibody, predicted molecular weight: 35 kDa)



12. Figure 8A-a

Treatment: AKI-48h (sham, IRI, IRI+LIPUS) Tissue: Kidney Protein: GAPDH (37 kDa)



13. Figure 8A-b

Treatment: AKI-48h (sham, IRI, IRI+LIPUS) Tissue: Spleen Protein: Ly6g (21-25 kDa)



14. Figure 8A-b

Treatment: AKI-48h (sham, IRI, IRI+LIPUS) Tissue: Spleen Protein: CD68 (polyclonal antibody, predicted molecular weight: 35 kDa)



15. Figure 8A-b

Treatment: AKI-48h (sham, IRI, IRI+LIPUS) Tissue: Spleen Protein: GAPDH (37 kDa)



shown in Fig. 8A-b